Latest Datamonitor Stories
Reportlinker.com announces that a new market research report related to the Consumer trends industry is available in its catalogue.
Research and Markets (http://www.researchandmarkets.com/reports/c74978) has announced the addition of Datamonitor's new report: The HP ALM Radars (Vendor Focus) to their offering. Introduction This brief analyses the strengths and weaknesses of HP's Application Lifecycle Management offering.
Given that BioMarin Pharmaceuticals's Kuvan is potentially the only treatment for the rare genetic metabolic disorder phenylketonuria, Datamonitor believes that Wall Street may be underestimating Kuvan's market potential.
Salix Pharmaceuticals' antibiotic Xifaxan was approved by the FDA for the treatment of traveler's diarrhea (TD) in 2004. However, the majority of Xifaxan use is accounted for by off-label indications, growth in which is essential to its revenue potential.
Allergan's memantine could offer a novel mechanism to slow glaucoma progression if the current phase III trial shows positive data.
By Ben Hirschler, European Pharmaceuticals Correspondent LONDON (Reuters) - The first copycat versions of biotech medicines could be approved in Europe later this year, while the United States is unlikely to get them before 2009, according to a report on Tuesday.
- Large; stout; burly.